Abstract
With the incidence and impact of atherosclerotic cardiovascular disease and its clinical manifestations still rising, therapeutic options that target the causal mechanisms of this disorder are highly desired. Since the CANTOS trial (Canakinumab Antiinflammatory Thrombosis Outcome Study) has demonstrated that lowering inflammation can be beneficial, focusing on mechanisms underlying inflammation, for example, leukocyte recruitment, is feasible. Being key orchestrators of leukocyte trafficking, chemokines have not lost their attractiveness as therapeutic targets, despite the difficult road to drug approval thus far. Still, innovative therapeutic approaches are being developed, paving the road towards the first chemokine-based therapeutic against inflammation. In this overview, recent developments for chemokines and for the chemokine-like factor MIF (macrophage migration inhibitory factor) will be discussed.
Original language | English |
---|---|
Pages (from-to) | 583-592 |
Number of pages | 10 |
Journal | Arteriosclerosis Thrombosis and Vascular Biology |
Volume | 39 |
Issue number | 4 |
DOIs | |
Publication status | Published - Apr 2019 |
Keywords
- atherosclerosis
- bone marrow
- cardiovascular disease
- chemokines
- myocardial infarction
- MIGRATION-INHIBITORY FACTOR
- CELL-DERIVED FACTOR-1-ALPHA
- LIMITS ATHEROSCLEROSIS
- INDEPENDENT PREDICTOR
- PLATELET ACTIVATION
- REPERFUSION INJURY
- VASCULAR INJURY
- CROSS-TALK
- FACTOR-I
- RECEPTOR